An Open,Multicentre,Prospective Study of Adjuvant Zoledronate Treatment in Osteoporosis Women With Breast Cancer

Trial Profile

An Open,Multicentre,Prospective Study of Adjuvant Zoledronate Treatment in Osteoporosis Women With Breast Cancer

Recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Breast cancer; Osteoporosis
  • Focus Therapeutic Use
  • Acronyms BLAZE
  • Most Recent Events

    • 17 Oct 2012 Planned end date changed from 1 Jun 2014 to 1 Jun 2017 as reported by ClinicalTrials.gov.
    • 26 Jun 2012 New trial record
    • 25 Jun 2012 Additional lead trial investigator (Shenming Wang) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top